Offer - Urjas Oil for just ₹ 1
Wilnaze-Xr is an allopathic medicine The correct dosage of Wilnaze-Xr depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Wilnaze-Xr is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Wilnaze-Xr safe for pregnant women?
Pregnant women can consume [medicine]. Though Wilnaze-Xr has mild side effects when taken during pregnany
Is the use of Wilnaze-Xr safe during breastfeeding?
Wilnaze-Xr may lead to some side effects in breastfeeding women. If you witness any unusal symptoms after taking Wilnaze-Xr, discontinue its use and call your doctor right away. Follow your doctor's advice regarding the use of Wilnaze-Xr.
What is the effect of Wilnaze-Xr on the Kidneys?
Wilnaze-Xr does not damage the kidneys.
What is the effect of Wilnaze-Xr on the Liver?
Wilnaze-Xr is not harmful for the liver.
What is the effect of Wilnaze-Xr on the Heart?
Wilnaze-Xr is completely safe for the heart.
Wilnaze-Xr should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Wilnaze-Xr unless your doctor advises you to do so -
Is this Wilnaze-Xr habit forming or addictive?
No, there is no any evidence that Wilnaze-Xr is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Wilnaze-Xr will not make you feel sleepy or drowsy. So you drive or operate machinery safely.
Is it safe?
Yes, but consume Wilnaze-Xr only on doctor's advice.
Is it able to treat mental disorders?
No, Wilnaze-Xr cannot treat any kind of mental disorder.
Interaction between Food and Wilnaze-Xr
Information is not available on the interaction of any foods with Wilnaze-Xr, due to a lack of research on this.
Interaction between Alcohol and Wilnaze-Xr
Consult your doctor before consuming alcohol while taking Wilnaze-Xr as it can have severe side effects.
Yes, you can take Wilnaze-Xr with a beta-blocker. People with diabetes tend to develop heart disease or stroke at an earlier age than the general population. One reason for this is that high glucose levels increase your risk of high blood pressure (hypertension). No harmful interactions are seen between them. However, a recent study suggests that beta-blockers can decrease the plasma level of Wilnaze-Xr and long-term use can increase lactic acid and uric acid in the blood.
Yes, you can take Wilnaze-Xr with gliclazide, no harmful interactions have been reported between them. However, it is not necessary that no interaction can happen between these two. But before taking such kind of combination you must consult your doctor.
The long-term use can lead to the deficiency of Vitamin B12, which can further lead to megaloblastic anemia. Furthermore, Long-term Metformin use can also lead to kidney and liver problems.
Wilnaze-Xr is not a known cause of alopecia (hair loss). However, the conditions treated by Wilnaze-Xr type 2 diabetes and PCOS, often list hair loss as a possible symptom.
Yes, Wilnaze-Xr commonly cause stomach upset like diarrhea, abdominal pain, nausea, and vomiting. To avoid these side effects you should take Wilnaze-Xr with your meal and increase the dose gradually.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826